For U.S. Residents Only

Take on aTTP with

CABLIVI is the first and only FDA-approved treatment for adults with aTTP in combination with plasma exchange and immunosuppressive therapy.*

Learn more about CABLIVI

Alex, real patient. Individual results may vary.
Alex is being compensated by Sanofi Genzyme.

Going from hospital to home

Learn about CABLIVI Patient solutions

Hear from real patients

Learn more about Patient stories

Your platelet counts matter

Learn how CABLIVI can help platelet counts

Claims are based on a clinical trial with 145 aTTP patients, of which 72 obtained CABLIVI with plasma exchange and immunosuppressive treatment. The remaining 73 patients got placebo (injection without active medicine) with plasma exchange and immunosuppressive treatment. Both groups got either CABLIVI or placebo during daily plasma exchange therapy and for 30 days afterward. After treatment was stopped, everyone was followed by their doctor for 28 more days. Study showed that patients treated with Cablivi achieved normal platelet count faster than patients in the placebo group. Also, 87% of Cablivi-treated patients were free of relapses during the treatment period and for 28 days after versus 62% of patients treated with placebo.

IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants. CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATIONS:
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

aTTP=acquired thrombotic thrombocytopenic purpura; TTP=thrombotic thrombocytopenic purpura.